Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Функциональная диагностика амилоидной кардиомиопатии в условиях практики и экспертных центров
Функциональная диагностика амилоидной кардиомиопатии в условиях практики и экспертных центров
Джиоева О.Н. Функциональная диагностика амилоидной кардиомиопатии в условиях практики и экспертных центров. Терапевтический архив. 2023;95(1):96–102. DOI: 10.26442/00403660.2023.01.202081
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Статья представляет собой свод рекомендаций по интерпретации данных электрокардио- и эхокардиографии у пациентов с подозрением на амилоидоз сердца. Амилоидная кардиомиопатия – прогрессирующее заболевание, которое характеризуется развернутой картиной застойной сердечной недостаточности, низким качеством жизни и плохим прогнозом. В настоящее время появились медикаментозные препараты, способные улучшить прогноз у пациентов с амилоидозом сердца. Повышение осведомленности специалистов о специфических инструментальных признаках заболевания является важной и актуальной задачей.
Ключевые слова: амилоидоз сердца, амилоидная кардиомиопатия, электрокардиография, эхокардиография, функциональная диагностика
Keywords: amyloidosis of the heart, amyloid cardiomyopathy, electrocardiography, echocardiography, functional diagnostics
Ключевые слова: амилоидоз сердца, амилоидная кардиомиопатия, электрокардиография, эхокардиография, функциональная диагностика
________________________________________________
Keywords: amyloidosis of the heart, amyloid cardiomyopathy, electrocardiography, echocardiography, functional diagnostics
Полный текст
Список литературы
1. Терещенко С.Н., Жиров И.В., Моисеева О.М., и др. Практические рекомендации по диагностике транстиретиновой амилоидной кардиомиопатии (ATTR-КМП или транстиретинового амилоидоза сердца). Терапевтический архив. 2022;94(4):584-95 [Tereshchenko SN, Zhirov IV, Moiseeva OM, et al. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(4):584-95 (in Russian)]. DOI:10.26442/00403660.2022.04.201465
2. Cavalcante JL, Rijal S, Abdelkarim I, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson. 2017;19(1):98. DOI:10.1186/s12968-017-0415-x
3. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114(7):1089-93. DOI:10.1016/j.amjcard.2014.07.026
4. Cappelli F, Vignini E, Martone R, et al. Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. Circ Heart Fail. 2020;13(3):e006619. DOI:10.1161/CIRCHEARTFAILURE.119.006619
5. Damy T, Maurer MS, Rapezzi C, et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016;3(1):e000289.
DOI:10.1136/openhrt-2015-000289
6. Dungu J, Sattianayagam PT, Whelan CJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J. 2012;164(1):72-9. DOI:10.1016/j.ahj.2012.04.013
7. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. DOI:10.1161/CIRCULATIONAHA.116.021612
8. Maurer MS, Hanna M, Grogan M, et al; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-72. DOI:10.1016/j.jacc.2016.03.596
9. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535-7. DOI:10.1016/j.amjcard.2004.10.028
10. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25(2):417-23. DOI:10.1016/0735-1097(94)00371-v
11. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. DOI:10.1161/CIRCULATIONAHA.108.843334
12. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520-8. DOI:10.1093/eurheartj/ehs123
13. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398-408. DOI:10.1038/nrcardio.2010.67
14. Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med. 1977;62(5):677-86. DOI:10.1016/0002-9343(77)90870-1
15. Ruberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-91. DOI:10.1016/j.jacc.2019.04.003
16. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477-81. DOI:10.1016/j.ijcard.2016.04.030
17. Zhao L, Li J, Tian Z, Fang Q. Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis. J Cardiol. 2016;68(5):426-30. DOI:10.1016/j.jjcc.2015.11.004
18. Cuddy SAM, Chetrit M, Jankowski M, et al. Practical Points for Echocardiography in Cardiac Amyloidosis. J Am Soc Echocardiogr. 2022;35(9):A31-40. DOI:10.1016/j.echo.2022.06.006
19. Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1-64. DOI:10.1016/j.echo.2018.06.004
20. AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6(11):1267-74. DOI:10.1001/jamacardio.2021.3070
2. Cavalcante JL, Rijal S, Abdelkarim I, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson. 2017;19(1):98. DOI:10.1186/s12968-017-0415-x
3. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114(7):1089-93. DOI:10.1016/j.amjcard.2014.07.026
4. Cappelli F, Vignini E, Martone R, et al. Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. Circ Heart Fail. 2020;13(3):e006619. DOI:10.1161/CIRCHEARTFAILURE.119.006619
5. Damy T, Maurer MS, Rapezzi C, et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016;3(1):e000289.
DOI:10.1136/openhrt-2015-000289
6. Dungu J, Sattianayagam PT, Whelan CJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J. 2012;164(1):72-9. DOI:10.1016/j.ahj.2012.04.013
7. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. DOI:10.1161/CIRCULATIONAHA.116.021612
8. Maurer MS, Hanna M, Grogan M, et al; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-72. DOI:10.1016/j.jacc.2016.03.596
9. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535-7. DOI:10.1016/j.amjcard.2004.10.028
10. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25(2):417-23. DOI:10.1016/0735-1097(94)00371-v
11. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. DOI:10.1161/CIRCULATIONAHA.108.843334
12. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520-8. DOI:10.1093/eurheartj/ehs123
13. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398-408. DOI:10.1038/nrcardio.2010.67
14. Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med. 1977;62(5):677-86. DOI:10.1016/0002-9343(77)90870-1
15. Ruberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-91. DOI:10.1016/j.jacc.2019.04.003
16. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477-81. DOI:10.1016/j.ijcard.2016.04.030
17. Zhao L, Li J, Tian Z, Fang Q. Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis. J Cardiol. 2016;68(5):426-30. DOI:10.1016/j.jjcc.2015.11.004
18. Cuddy SAM, Chetrit M, Jankowski M, et al. Practical Points for Echocardiography in Cardiac Amyloidosis. J Am Soc Echocardiogr. 2022;35(9):A31-40. DOI:10.1016/j.echo.2022.06.006
19. Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1-64. DOI:10.1016/j.echo.2018.06.004
20. AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6(11):1267-74. DOI:10.1001/jamacardio.2021.3070
2. Cavalcante JL, Rijal S, Abdelkarim I, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson. 2017;19(1):98. DOI:10.1186/s12968-017-0415-x
3. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114(7):1089-93. DOI:10.1016/j.amjcard.2014.07.026
4. Cappelli F, Vignini E, Martone R, et al. Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. Circ Heart Fail. 2020;13(3):e006619. DOI:10.1161/CIRCHEARTFAILURE.119.006619
5. Damy T, Maurer MS, Rapezzi C, et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016;3(1):e000289.
DOI:10.1136/openhrt-2015-000289
6. Dungu J, Sattianayagam PT, Whelan CJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J. 2012;164(1):72-9. DOI:10.1016/j.ahj.2012.04.013
7. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. DOI:10.1161/CIRCULATIONAHA.116.021612
8. Maurer MS, Hanna M, Grogan M, et al; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-72. DOI:10.1016/j.jacc.2016.03.596
9. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535-7. DOI:10.1016/j.amjcard.2004.10.028
10. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25(2):417-23. DOI:10.1016/0735-1097(94)00371-v
11. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. DOI:10.1161/CIRCULATIONAHA.108.843334
12. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520-8. DOI:10.1093/eurheartj/ehs123
13. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398-408. DOI:10.1038/nrcardio.2010.67
14. Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med. 1977;62(5):677-86. DOI:10.1016/0002-9343(77)90870-1
15. Ruberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-91. DOI:10.1016/j.jacc.2019.04.003
16. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477-81. DOI:10.1016/j.ijcard.2016.04.030
17. Zhao L, Li J, Tian Z, Fang Q. Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis. J Cardiol. 2016;68(5):426-30. DOI:10.1016/j.jjcc.2015.11.004
18. Cuddy SAM, Chetrit M, Jankowski M, et al. Practical Points for Echocardiography in Cardiac Amyloidosis. J Am Soc Echocardiogr. 2022;35(9):A31-40. DOI:10.1016/j.echo.2022.06.006
19. Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1-64. DOI:10.1016/j.echo.2018.06.004
20. AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6(11):1267-74. DOI:10.1001/jamacardio.2021.3070
________________________________________________
2. Cavalcante JL, Rijal S, Abdelkarim I, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson. 2017;19(1):98. DOI:10.1186/s12968-017-0415-x
3. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114(7):1089-93. DOI:10.1016/j.amjcard.2014.07.026
4. Cappelli F, Vignini E, Martone R, et al. Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. Circ Heart Fail. 2020;13(3):e006619. DOI:10.1161/CIRCHEARTFAILURE.119.006619
5. Damy T, Maurer MS, Rapezzi C, et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016;3(1):e000289.
DOI:10.1136/openhrt-2015-000289
6. Dungu J, Sattianayagam PT, Whelan CJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J. 2012;164(1):72-9. DOI:10.1016/j.ahj.2012.04.013
7. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12. DOI:10.1161/CIRCULATIONAHA.116.021612
8. Maurer MS, Hanna M, Grogan M, et al; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-72. DOI:10.1016/j.jacc.2016.03.596
9. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535-7. DOI:10.1016/j.amjcard.2004.10.028
10. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25(2):417-23. DOI:10.1016/0735-1097(94)00371-v
11. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. DOI:10.1161/CIRCULATIONAHA.108.843334
12. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520-8. DOI:10.1093/eurheartj/ehs123
13. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398-408. DOI:10.1038/nrcardio.2010.67
14. Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med. 1977;62(5):677-86. DOI:10.1016/0002-9343(77)90870-1
15. Ruberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-91. DOI:10.1016/j.jacc.2019.04.003
16. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477-81. DOI:10.1016/j.ijcard.2016.04.030
17. Zhao L, Li J, Tian Z, Fang Q. Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis. J Cardiol. 2016;68(5):426-30. DOI:10.1016/j.jjcc.2015.11.004
18. Cuddy SAM, Chetrit M, Jankowski M, et al. Practical Points for Echocardiography in Cardiac Amyloidosis. J Am Soc Echocardiogr. 2022;35(9):A31-40. DOI:10.1016/j.echo.2022.06.006
19. Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1-64. DOI:10.1016/j.echo.2018.06.004
20. AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6(11):1267-74. DOI:10.1001/jamacardio.2021.3070
Авторы
О.Н. Джиоева*
ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России, Москва, Россия;
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*dzhioevaon@gmail.com
National Research Center for Therapy and Preventive Medicine, Moscow, Russia;
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*dzhioevaon@gmail.com
ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России, Москва, Россия;
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*dzhioevaon@gmail.com
________________________________________________
National Research Center for Therapy and Preventive Medicine, Moscow, Russia;
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*dzhioevaon@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.